Remove FDA Approval Remove Life Science Remove Pharmacy
article thumbnail

Journey Medical’s Emrosi Wins FDA Approval for Rosacea, Could Rival Galderma’s Oracea

XTalks

Journey Medical plans to make Emrosi available by early 2025 through dermatology clinics and pharmacies across the US. Maraoui said the company’s dermatology-focused sales force is “now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea.”

article thumbnail

Konvomep Gets FDA Approval as a New Oral Liquid Formulation Option of Omeprazole

XTalks

On Friday, Azurity Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved their innovative oral liquid formulation Konvomep (omeprazole and sodium bicarbonate for oral suspension). John’s University College of Pharmacy & Health Sciences, Queens, New York.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Acute Leukemia Drug Revuforj Wins FDA Approval, Second Approval for Syndax this Year

XTalks

Syndax Pharmaceuticals’ Revuforj (revumenib) has won US Food and Drug Administration (FDA) approval for the treatment of relapsed or refractory (R/R) acute leukemia in patients aged one year and older who have a lysine methyltransferase 2A ( KMT2A, formerly MLL ) gene translocation.

article thumbnail

Ogsiveo Receives FDA Approval as First Therapy for Desmoid Tumors

XTalks

Pfizer spinout SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has received US Food and Drug Administration (FDA) approval for the treatment of desmoid tumors, an ultra-rare subtype of non-cancerous soft tissue sarcomas that can cause severe pain and disfigurement.

article thumbnail

Verrica’s Dr. Lawrence Eichenfield Speaks About FDA Approval of New Drug for Common Skin Infection – Xtalks Life Science Podcast Ep. 121

XTalks

Eichenfield serves on Verrica Pharmaceuticals’ Board of Directors and spoke to Xtalks about the company’s recent approval of YCANTH (cantharidin) topical solution as the first FDA approved treatment for pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection that primarily affects children.

article thumbnail

FDA Approves Dong-A ST’s Imuldosa (Ustekinumab), a Stelara Biosimilar

XTalks

Stelara Price Reductions and Expanding Biosimilar Competition Imuldosa’s approval joins a wave of Stelara biosimilars. In October 2023, Amgen’s Wezlana (ustekinumab-auub) became an interchangeable biosimilar approved by the FDA, eligible for pharmacy-level substitution.

article thumbnail

FDA Approves First Eylea Interchangeable Biosimilars Yesafili and Opuviz

XTalks

Yesafili and Opuviz are approved to treat the same conditions as Regeneron’s vascular endothelial growth factor (VEGF) inhibitor Eylea — neovascular (wet) age-related macular degeneration (AMD), diabetic retinopathy, macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME). According to Biocon, there are 19.8